Survival over two decades in neuroendocrine neoplasms care.

Authors

Julie Hallet, Léamarie Meloche-Dumas, Carlotta Sarzo, Jessica Armah, Anna Ding, Wing Chan, Simron Singh

Published in

JNCI cancer spectrum. Oct 14, 2026. Epub Oct 14, 2026.

Abstract

The incidence of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) has increased, alongside novel therapies and care models. Whether these advances translated into improved survival is unclear.
Population-based retrospective cohort study of GEP-NENs between 2000-2019. Overall survival (OS) was analyzed using time-to-event methods. Restricted cubic splines assessed non-linear associations between diagnosis year and hazards of death; multivariable Cox regression adjusted for age, sex, primary site, and metastatic status.
Among 9,420 patients, 5-year OS was 75.8% overall, 88.8% for non-metastatic disease, and 57.0% for metastatic disease. Mortality risk declined in more recent years, with diagnoses in 2013-2019 associated with lower hazards of death (adjusted HR 0.91, 95%CI 0.83-0.99). Improvements were confined to non-metastatic disease and to pancreas, stomach, and rectal primaries.
OS has modestly improved over two decades, largely reflecting stage migration rather than clear therapeutic gains. Advances that meaningfully improve survival in advanced GEP-NENs are needed.

PMID:
42873586
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.